197 related articles for article (PubMed ID: 34858729)
1. Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.
Kim JH; Lee WS; Lee HJ; Yang H; Lee SJ; Kong SJ; Je S; Yang HJ; Jung J; Cheon J; Kang B; Chon HJ; Kim C
Oncoimmunology; 2021; 10(1):2005280. PubMed ID: 34858729
[TBL] [Abstract][Full Text] [Related]
2. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
3. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
4. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry.
Nguyen TT; Shin DH; Sohoni S; Singh SK; Rivera-Molina Y; Jiang H; Fan X; Gumin J; Lang FF; Alvarez-Breckenridge C; Godoy-Vitorino F; Zhu L; Zheng WJ; Zhai L; Ladomersky E; Lauing KL; Alonso MM; Wainwright DA; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902132
[TBL] [Abstract][Full Text] [Related]
5. Reversal of indoleamine 2,3-dioxygenase-mediated cancer immune suppression by systemic kynurenine depletion with a therapeutic enzyme.
Triplett TA; Garrison KC; Marshall N; Donkor M; Blazeck J; Lamb C; Qerqez A; Dekker JD; Tanno Y; Lu WC; Karamitros CS; Ford K; Tan B; Zhang XM; McGovern K; Coma S; Kumada Y; Yamany MS; Sentandreu E; Fromm G; Tiziani S; Schreiber TH; Manfredi M; Ehrlich LIR; Stone E; Georgiou G
Nat Biotechnol; 2018 Sep; 36(8):758-764. PubMed ID: 30010674
[TBL] [Abstract][Full Text] [Related]
6. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
7. IDO/kynurenine pathway in cancer: possible therapeutic approaches.
Abd El-Fattah EE
J Transl Med; 2022 Aug; 20(1):347. PubMed ID: 35918736
[TBL] [Abstract][Full Text] [Related]
8. Tryptophan: A Rheostat of Cancer Immune Escape Mediated by Immunosuppressive Enzymes IDO1 and TDO.
Kim M; Tomek P
Front Immunol; 2021; 12():636081. PubMed ID: 33708223
[TBL] [Abstract][Full Text] [Related]
9. Kynurenine produced by indoleamine 2,3-dioxygenase 2 exacerbates acute liver injury by carbon tetrachloride in mice.
Hoshi M; Osawa Y; Nakamoto K; Morita N; Yamamoto Y; Ando T; Tashita C; Nabeshima T; Saito K
Toxicology; 2020 May; 438():152458. PubMed ID: 32289347
[TBL] [Abstract][Full Text] [Related]
10. Peripheral kynurenine/tryptophan ratio is not a reliable marker of systemic indoleamine 2,3-dioxygenase: A lesson drawn from patients on hemodialysis.
Chen Y; Xie Z; Xiao C; Zhang M; Li Z; Xie J; Zhang Y; Zhao X; Zeng P; Mo L; Liang X; Shi W
Oncotarget; 2017 Apr; 8(15):25261-25269. PubMed ID: 28445957
[TBL] [Abstract][Full Text] [Related]
11. Can IDO activity predict primary resistance to anti-PD-1 treatment in NSCLC?
Botticelli A; Cerbelli B; Lionetto L; Zizzari I; Salati M; Pisano A; Federica M; Simmaco M; Nuti M; Marchetti P
J Transl Med; 2018 Aug; 16(1):219. PubMed ID: 30081936
[TBL] [Abstract][Full Text] [Related]
12. Both IDO1 and TDO contribute to the malignancy of gliomas via the Kyn-AhR-AQP4 signaling pathway.
Du L; Xing Z; Tao B; Li T; Yang D; Li W; Zheng Y; Kuang C; Yang Q
Signal Transduct Target Ther; 2020 Feb; 5(1):10. PubMed ID: 32296044
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel kynurenine production-inhibiting benzenesulfonamide derivatives in cancer cells.
Nakano S; Takai K; Isaka Y; Takahashi S; Unno Y; Ogo N; Matsuno K; Takikawa O; Asai A
Biochem Biophys Res Commun; 2012 Mar; 419(3):556-61. PubMed ID: 22369947
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and in vivo antitumor evaluation of an orally active potent phosphonamidate derivative targeting IDO1/IDO2/TDO.
Feng X; Shen P; Wang Y; Li Z; Bian J
Biochem Pharmacol; 2019 Oct; 168():214-223. PubMed ID: 31306643
[TBL] [Abstract][Full Text] [Related]
15. Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.
Wells G; Kennedy PT; Dahal LN
Front Immunol; 2021; 12():651687. PubMed ID: 33777052
[No Abstract] [Full Text] [Related]
16. Comparative effects of oxygen on indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase of the kynurenine pathway.
Dang Y; Dale WE; Brown OR
Free Radic Biol Med; 2000 Feb; 28(4):615-24. PubMed ID: 10719243
[TBL] [Abstract][Full Text] [Related]
17. Cell cycle arrest by kynurenine in lens epithelial cells.
Mailankot M; Smith D; Howell S; Wang B; Jacobberger JW; Stefan T; Nagaraj RH
Invest Ophthalmol Vis Sci; 2008 Dec; 49(12):5466-75. PubMed ID: 18676626
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2, 3-dioxygenase inhibitors in immunochemotherapy of breast cancer: challenges and opportunities.
Hashemzadeh N; Adibkia K; Barar J
Bioimpacts; 2019; 9(1):1-3. PubMed ID: 30788254
[TBL] [Abstract][Full Text] [Related]
19. Redox reactions related to indoleamine 2,3-dioxygenase and tryptophan metabolism along the kynurenine pathway.
Thomas SR; Stocker R
Redox Rep; 1999; 4(5):199-220. PubMed ID: 10731095
[TBL] [Abstract][Full Text] [Related]
20. L-tryptophan-kynurenine pathway metabolites regulate type I IFNs of acute viral myocarditis in mice.
Hoshi M; Matsumoto K; Ito H; Ohtaki H; Arioka Y; Osawa Y; Yamamoto Y; Matsunami H; Hara A; Seishima M; Saito K
J Immunol; 2012 Apr; 188(8):3980-7. PubMed ID: 22422885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
